Number of the records: 1  

Human adipose tissue-derived mesenchymal stem cells expressing yeast cytosinedeaminase::uracil phosphoribosyltransferase inhibit intracerebral rat glioblastoma

  1. 1.
    SYSNO ASEP0376021
    Document TypeJ - Journal Article
    R&D Document TypeJournal Article
    Subsidiary JČlánek ve WOS
    TitleHuman adipose tissue-derived mesenchymal stem cells expressing yeast cytosinedeaminase::uracil phosphoribosyltransferase inhibit intracerebral rat glioblastoma
    Author(s) Altanerova, V. (SK)
    Cihova, M. (SK)
    Babič, Michal (UMCH-V) RID, ORCID
    Rychly, B. (SK)
    Ondicova, K. (SK)
    Mravec, B. (SK)
    Altaner, C. (SK)
    Source TitleInternational Journal of Cancer. - : Wiley - ISSN 0020-7136
    Roč. 130, č. 10 (2012), s. 2455-2463
    Number of pages9 s.
    Languageeng - English
    CountryDE - Germany
    Keywordsglioblastoma ; mesenchymal stem cells ; suicide gene therapy
    Subject RIVCD - Macromolecular Chemistry
    CEZAV0Z40500505 - UMCH-V (2005-2011)
    UT WOS000301579800025
    DOI10.1002/ijc.26278
    AnnotationHuman adipose tissue-derived MSCs to express the suicide gene cytosine deaminase::uracil phosphoribosyltransferase to treat intracranial rat C6 glioblastoma was tested. Experiments simulated conditions of future clinical application for high-grade glioblastoma therapy by direct injections of therapeutic stem cells into tumor. Genetically modified therapeutic stem cells showed the tumor tropism when injected to a distant intracranial site and effectively inhibited glioblastoma growth after 5-fluorocytosine (5-FC) therapy. Coadministration of C6 cells and therapeutic stem cells with delayed 5-FC therapy improved the survival in a therapeutic stem cell dose-dependent manner and induced complete tumor regression. Continuous intracerebroventricular delivery of 5-FC using osmotic pump reduced the dose of prodrug required for the same therapeutic effect, and along with repeated administration of therapeutic stem cells increased the survival time without any detectable adverse effects.
    WorkplaceInstitute of Macromolecular Chemistry
    ContactEva Čechová, cechova@imc.cas.cz ; Tel.: 296 809 358
    Year of Publishing2013
Number of the records: 1  

  This site uses cookies to make them easier to browse. Learn more about how we use cookies.